Goldman Sachs names 40 stocks to buy before they surge to meet its higher price targets – including 5 with more than 50% upside
Sunday, 11 April 2021, 12:30:00
Summary List Placement Markets saw a strong start to the second quarter. The S&P 500 rose to a record high on April 1 and surpassed 4,000 points for the first time on the back of increased confidence in the economy that stemmed from vaccinations and Biden's infrastructure plan. During the first quarter, all 11 stock-market sectors saw gains . Cyclicals were the biggest winners, with the energy, financials, and industrial sectors posting double-digit gains during that period given that they are closely correlated with the fluctuations of the economy. And although the utilities, tech, and consumer staples areas still enjoyed some returns, they ended up performing the worst. However, since reaching record highs, stocks have proceeded to trade in a flat manner. But that might change soon enough as earnings season kicks off this week with big banks like JPMorgan and Bank of America sharing their financial reports with investors. Investors assess earnings to determine a company's profitability and use earnings per share as a metric to estimate its valuation.
— Business Insider
Eli Lilly-Incyte's Baricitinib Study In Hospitalized COVID-19 Patients Fails To Meet Main Goal
Thursday, 8 April 2021, 13:41:32
Eli Lilly And Co (NYSE: LLY ) and Incyte Corporation (NASDAQ: INCY ) have reported results from the COV-BARRIER Phase 3 study evaluating baricitinib plus standard of care (SoC) versus placebo plus SoC in hospitalized COVID-19 patients. The trial did not meet statistical significance on the primary endpoint of the proportion of participants progressing to non-invasive ventilation or death by Day 28. Baricitinib-treated patients were 2.7% less likely than those receiving standard of care to … Full story available on Benzinga.com
Is Silicon Valley Replacing Big Pharma In Neuroscience?
Tuesday, 6 April 2021, 14:54:07
The following article is sponsored by Mind Cure. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only. Over the past decade, big pharma has largely stepped away from the research and development of psychiatric drugs. This came after what was a fruitful period for the pharmaceutical industry during the 1990s and early 2000s. This renaissance was caused largely in part to the release of Eli Lilly And Co’s (NYSE: LLY ) Prozac, an antidepressant, in 1988. This SSRI (Selective Serotonin Reuptake Inhibitor) was seen as a major development in the field of neuroscience. Although since then, many major pharmaceutical companies have either devoted fewer resources to neurological research or have cut spending altogether. The industry has seen this with companies such as Pfizer Inc. (NYSE: PFE ), Amgen, Inc. (NASDAQ: AMGN ), AstraZeneca plc (NASDAQ: AZN ), Eli & Lily and Merck & Co., Inc. (NYSE: MRK ), among others.
Fortress Biotech's Partner Firm Expands Footprint In Dermatology With Qbrexza Acquisition
Thursday, 1 April 2021, 15:02:28
Fortress Biotech Inc's (NASDAQ: FBIO ) partner company Journey Medical Corporation has agreed to acquire Qbrexza (glycopyrronium) in the U.S. from Dermira Inc , a wholly-owned subsidiary of Eli Lilly And Co (NYSE: LLY ). The transaction … Full story available on Benzinga.com
Scientists are coming around to a surprising new understanding of Alzheimer's disease, and it could supercharge drug development for the $1.1 trillion problem
Monday, 29 March 2021, 17:01:40
Summary List Placement In January, at the World Economic Forum's annual gathering of some of the globe's richest and most powerful leaders, Andrea Pfeifer was promoting her biotech company and a new global initiative to treat Alzheimer's. During a Q&A session, George Vradenburg , the entertainment lawyer turned philanthropist, asked her a question about her work: “Is Alzheimer's not one disease?” “It's definitely not one disease,” she replied. That theory has been floating around for years, creating some controversy among neuroscientists. But Pfeifer, the chief executive of the small biotech AC Immune, said that when she declared her view of Alzheimer's during the virtual meeting, the audience was receptive. Alzheimer's has been creeping up on countries across the globe like a slow pandemic. And it's sinking in that researchers, financiers, and world leaders need to completely change the way they approach creating treatments. The once controversial idea that Alzheimer's is in fact a highly varied disease, if not multiple distinct but related conditions, is gaining traction and could unlock new approaches to treating it.
— Business Insider
We recommend that you check out Capital.com as they have a very good selection of stocks available for both going short and long.